[go: up one dir, main page]

HUE037487T2 - Tetrahidropirrolotiazin vegyületek - Google Patents

Tetrahidropirrolotiazin vegyületek

Info

Publication number
HUE037487T2
HUE037487T2 HUE14712875A HUE14712875A HUE037487T2 HU E037487 T2 HUE037487 T2 HU E037487T2 HU E14712875 A HUE14712875 A HU E14712875A HU E14712875 A HUE14712875 A HU E14712875A HU E037487 T2 HUE037487 T2 HU E037487T2
Authority
HU
Hungary
Prior art keywords
tetrahydropyrrolothiazine
compounds
tetrahydropyrrolothiazine compounds
Prior art date
Application number
HUE14712875A
Other languages
English (en)
Inventor
Steven James Green
Dustin James Mergott
Brian Morgan Watson
Jr Leonard Larry Winneroski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUE037487T2 publication Critical patent/HUE037487T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HUE14712875A 2013-03-12 2014-03-04 Tetrahidropirrolotiazin vegyületek HUE037487T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361776819P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
HUE037487T2 true HUE037487T2 (hu) 2018-08-28

Family

ID=50382615

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14712875A HUE037487T2 (hu) 2013-03-12 2014-03-04 Tetrahidropirrolotiazin vegyületek

Country Status (37)

Country Link
US (3) US8841293B1 (hu)
EP (1) EP2970336B1 (hu)
JP (1) JP6095844B2 (hu)
KR (1) KR101688761B1 (hu)
CN (1) CN105026404B (hu)
AP (1) AP2015008713A0 (hu)
AR (1) AR094918A1 (hu)
BR (1) BR112015018738A8 (hu)
CA (1) CA2898500C (hu)
CL (1) CL2015002529A1 (hu)
CR (1) CR20150418A (hu)
CY (1) CY1119585T1 (hu)
DK (1) DK2970336T3 (hu)
EA (1) EA026006B1 (hu)
ES (1) ES2653421T3 (hu)
HR (1) HRP20171851T1 (hu)
HU (1) HUE037487T2 (hu)
IL (1) IL240903B (hu)
JO (1) JO3317B1 (hu)
LT (1) LT2970336T (hu)
MA (1) MA38390B1 (hu)
ME (1) ME02910B (hu)
MX (1) MX2015012628A (hu)
MY (1) MY180083A (hu)
NO (1) NO3039297T3 (hu)
NZ (1) NZ712207A (hu)
PE (1) PE20151542A1 (hu)
PH (1) PH12015502031A1 (hu)
PL (1) PL2970336T3 (hu)
PT (1) PT2970336T (hu)
RS (1) RS56645B1 (hu)
SG (1) SG11201507499XA (hu)
SI (1) SI2970336T1 (hu)
TN (1) TN2015000340A1 (hu)
TW (1) TWI593692B (hu)
UA (1) UA112941C2 (hu)
WO (1) WO2014143579A1 (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
ES2753163T3 (es) 2012-09-25 2020-04-07 Hoffmann La Roche Derivados de hexahidropirrolo[3,4-c]pirrol y compuestos relacionados como inhibidores de la autotaxina (ATX) y como inhibidores de la producción de ácido lisofosfatídico (LPA) para tratar, por ejemplo, enfermedades renales
CN104755484B (zh) 2012-10-26 2016-02-17 伊莱利利公司 Bace抑制剂
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
CA2923523A1 (en) 2013-11-26 2015-06-04 F. Hoffmann-La Roche Ag New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
TWI684452B (zh) 2014-03-14 2020-02-11 美國禮來大藥廠 胺基噻嗪化合物
JP6554481B2 (ja) 2014-03-26 2019-07-31 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft オートタキシン(atx)及びリゾホスファチジン酸(lpa)産生の阻害剤としての縮合[1,4]ジアゼピン化合物
SG11201607839UA (en) 2014-03-26 2016-10-28 Hoffmann La Roche Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
TWI570127B (zh) * 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
AR103406A1 (es) * 2015-01-30 2017-05-10 Lilly Co Eli Sal de tosilato
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
EP3353181B1 (en) 2015-09-24 2021-08-11 F. Hoffmann-La Roche AG Bicyclic compounds as dual atx/ca inhibitors
CA2983782A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
JP6877413B2 (ja) 2015-09-24 2021-05-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二重atx/ca阻害剤としての新規な二環式化合物
WO2017050792A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
TW201740954A (zh) 2016-03-16 2017-12-01 美國禮來大藥廠 組合療法
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗-N3pGlu類澱粉β肽抗體及其用途
EP3555084B1 (en) 2016-12-15 2022-03-16 Amgen Inc. Thiazine derivatives as beta-secretase inhibitors and methods of use
US11548903B2 (en) 2016-12-15 2023-01-10 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
MA52722A (fr) 2016-12-15 2021-04-14 Amgen Inc Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
AU2017376446B2 (en) 2016-12-15 2021-10-14 Amgen Inc. 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
AU2017378316B2 (en) 2016-12-15 2021-04-01 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
KR20190129924A (ko) 2017-03-16 2019-11-20 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 유용한 헤테로환형 화합물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2003082856A1 (en) * 2002-03-22 2003-10-09 Eli Lilly And Company Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists
BRPI0612072A2 (pt) * 2005-06-14 2010-10-19 Schering Corp inibidores da aspartil protease
KR101052122B1 (ko) 2005-10-25 2011-07-26 시오노기세야쿠 가부시키가이샤 아미노디히드로티아진 유도체
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
US20100317850A1 (en) * 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
MX2010011563A (es) 2008-04-22 2010-11-12 Schering Corp Compuestos 2-imino-3-metil pirrolo pirimidinona fenil-sustituidos como inhibidores de enzima de escision de proteina precursora amiloide sitio beta-1, composiciones y su uso.
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Bace抑制劑
AU2009258496B8 (en) 2008-06-13 2014-06-26 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
MX2011003189A (es) 2008-09-30 2011-04-27 Eisai R&D Man Co Ltd Nuevo derivado de aminodihidrotiazina fusionada.
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
EP2511269A4 (en) 2009-12-11 2013-04-24 Shionogi & Co FUSED HETEROCYCLIC COMPOUND HAVING AN AMINO GROUP
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2012162334A1 (en) 2011-05-24 2012-11-29 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
JO3143B1 (ar) * 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين

Also Published As

Publication number Publication date
ME02910B (me) 2018-04-20
ES2653421T3 (es) 2018-02-07
JP6095844B2 (ja) 2017-03-15
LT2970336T (lt) 2018-01-10
PH12015502031B1 (en) 2016-01-18
PL2970336T3 (pl) 2018-03-30
US8987254B2 (en) 2015-03-24
AU2014228351A1 (en) 2015-09-17
CL2015002529A1 (es) 2016-03-28
MY180083A (en) 2020-11-20
UA112941C2 (uk) 2016-11-10
BR112015018738A8 (pt) 2018-01-23
RS56645B1 (sr) 2018-03-30
PT2970336T (pt) 2017-12-21
JO3317B1 (ar) 2019-03-13
EA026006B1 (ru) 2017-02-28
CY1119585T1 (el) 2018-03-07
CR20150418A (es) 2015-09-16
TW201520217A (zh) 2015-06-01
MX2015012628A (es) 2016-07-07
KR20150119070A (ko) 2015-10-23
HK1212694A1 (en) 2016-06-17
KR101688761B1 (ko) 2016-12-21
WO2014143579A1 (en) 2014-09-18
MA38390B1 (fr) 2020-01-31
NO3039297T3 (hu) 2018-03-10
AP2015008713A0 (en) 2015-09-30
MA38390A1 (fr) 2018-08-31
US8841293B1 (en) 2014-09-23
US20140350245A1 (en) 2014-11-27
AR094918A1 (es) 2015-09-09
NZ712207A (en) 2019-09-27
EP2970336B1 (en) 2017-10-04
CA2898500C (en) 2017-11-14
BR112015018738A2 (pt) 2017-07-18
US20150157641A1 (en) 2015-06-11
CN105026404B (zh) 2016-11-23
TWI593692B (zh) 2017-08-01
IL240903A0 (en) 2015-10-29
SI2970336T1 (sl) 2017-11-30
PH12015502031A1 (en) 2016-01-18
IL240903B (en) 2018-12-31
JP2016512252A (ja) 2016-04-25
HRP20171851T1 (hr) 2018-01-12
EP2970336A1 (en) 2016-01-20
US20140275044A1 (en) 2014-09-18
EA201591491A1 (ru) 2016-01-29
PE20151542A1 (es) 2015-10-28
CA2898500A1 (en) 2014-09-18
TN2015000340A1 (en) 2017-01-03
SG11201507499XA (en) 2015-10-29
DK2970336T3 (da) 2017-11-13
CN105026404A (zh) 2015-11-04

Similar Documents

Publication Publication Date Title
IL240903B (en) Tetrahydropyrrolothiazine compounds
GB201309085D0 (en) Compounds
GB201310542D0 (en) Compounds
GB201302927D0 (en) Compounds
GB201311951D0 (en) Compounds
GB201309508D0 (en) Compounds
GB201317619D0 (en) Compounds
GB201319363D0 (en) Compounds
GB201320636D0 (en) Compounds
GB201311953D0 (en) Compounds
AP3850A (en) Azetidinyloxyphenylpyrrolidine compounds
GB201312901D0 (en) Compounds
EP2948457A4 (en) COMPOUNDS
GB201306794D0 (en) Compounds
GB201318461D0 (en) Compounds
GB201310460D0 (en) Compounds
GB201322855D0 (en) Compounds
GB201322028D0 (en) Compounds
GB201321553D0 (en) Compounds
GB201321554D0 (en) Compounds
GB201321283D0 (en) Compounds
GB201318323D0 (en) Compounds
GB201318143D0 (en) Compounds
GB201317118D0 (en) Compounds
GB201315947D0 (en) Compounds